128 Abstracts Evaluating Celgene Products to Be Presented at the 50^th Annual American Society of Hematology Meeting

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) today announced that clinical investigators from leading hematology research centers around the world will present data from recent and on-going clinical trials of multiple Celgene products at the 50^th Annual American Society of Hematology Meeting and Exposition from December 6-9, 2008 in San Francisco, California. Nearly 130 posters and presentations will report important new findings in indications such as multiple myeloma, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, myelodysplastic syndromes, amyloidosis and myelofibrosis.

Key abstracts include:

Multiple Myeloma

#91 – (Oral) PHASE II TRIAL OF LENALIDOMIDE WITH CYCLOPHOSPHAMIDE AND DEXAMETHASONE FOR NEWLY DIAGNOSED MYELOMA – Sunday, Dec. 7, 2008, 4:30 p.m.

#92 (Oral) LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: ENCOURAGING EFFICACY IN HIGH RISK GROUPS WITH UPDATED RESULTS OF A PHASE I/II STUDY – Sunday, Dec. 7, 2008, 4:45 p.m.

#93 (Oral) SAFETY AND EFFICACY OF NOVEL COMBINATION THERAPY WITH BORTEZOMIB, DEXAMETHASONE, CYCLOPHOSPHAMIDE, AND LENALIDOMIDE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: INITIAL RESULTS FROM THE PHASE I/II MULTI-CENTER EVOLUTION STUDY – Sunday, Dec. 7, 2008, 5 p.m.

#95 (Oral) SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MYELOMA UNDERGOING THERAPY WITH LENALIDOMIDE AND DEXAMETHASONE: IMPACT OF HIGH-RISK CYTOGENETIC RISK STATUS ON OUTCOME – Sunday, Dec. 7, 2008, 5:30 p.m.

#655 – (Oral) IMPROVED SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA AFTER THE INTRODUCTION OF NOVEL AGENTS AND THE APPLICABILITY OF THE INTERNATIONAL STAGING SYSTEM (ISS) AN ANALYSIS OF THE GREEK MYELOMA STUDY GROUP (GMSG) – Monday, Dec. 8, 2008, 5 p.m.

#866 – (Oral) POMALIDOMIDE (CC-4047) PLUS LOW-DOSE DEXAMETHASONE IS A HIGHLY EFFECTIVE THERAPY IN RELAPSED MULTIPLE MYELOMA – Tuesday, Dec. 9, 2008, 7:30 a.m.

#868 – (Oral) COMBINATION OF LENALIDOMIDE, MELPHALAN, PREDNISONE AND THALIDOMIDE (RMPT) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: RESULTS OF A MULTICENTER PHASE II CLINICAL TRIAL – Tuesday, Dec. 9, 2008, 8 a.m.

#1696 – (Poster) REGULATORY T CELLS (TREG) ARE DEPRESSED IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA (MM) AND INCREASES TOWARDS NORMAL RANGE IN RESPONDING PATIENTS TREATED WITH LENALIDOMIDE (LEN) - Saturday, Dec. 6, 2008, 5:30 p.m.

#1731 – (Poster) THE IMPACT OF CYTOGENETICS ON THE OUTCOMES OF TREATMENT WITH LENALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA - Saturday, Dec. 6, 2008: 5:30 p.m.

#1742 – (Poster) LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM): ENCOURAGING RESPONSE RATES AND TOLERABILITY WITH CORRELATION OF OUTCOME AND ADVERSE CYTOGENETICS IN A PHASE II STUDY – Saturday, Dec. 6, 2008, 5:30 p.m.

#1729 – (Poster) PROGNOSTIC IMPACT OF THE PLASMA CELL LABELING INDEX (LI) IN NEWLY DIAGNOSED MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE OR LENALIDOMIDE-DEXAMETHASONE – Saturday, Dec. 6, 2008, 5:30 p.m.

#2761 – (Poster) OPPOSING EFFECTS OF DEXAMETHASONE ON LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA: ADDITIVE/SYNERGISTIC EFFECTS ON ANTI-PROLIFERATIVE ACTIVITY ON MYELOMA CELLS AND ANTAGONISTIC EFFECTS ON IMMUNE FUNCTION – Sunday, Dec. 7, 2008: 6 p.m.

#2769 – (Poster) PHASE II STUDY OF MELPHALAN, PREDNISONE AND LENALIDOMIDE IN COMBINATION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WHO ARE NOT CANDIDATES FOR STEM CELL TRANSPLANTATION – Sunday, Dec. 7, 2008, 6 p.m.

#3702 – (Poster) LONGER DURATION OF TREATMENT AND MAINTENANCE OF BEST RESPONSE WITH LENALIDOMIDE AND DEXAMETHASONE PROLONGS OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA – Monday, Dec. 8, 2008, 5:30 p.m.

#3701 – (Poster) SAFETY AND EFFICACY OUTCOMES WITH LENALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA WERE NOT SIGNIFICANTLY DIFFERENT FOR THE TREATMENT OF PATIENTS WITH OR WITHOUT HIGH-RISK DISEASE OR ELDERLY STATUS – Monday, Dec. 8, 2008: 5:30 p.m.

#3708 – (Poster) DECLINING RATES OF ADVERSE EVENTS AND DOSE MODIFICATIONS WITH LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE – Monday, Dec. 8, 2008, 5:30 p.m.

#3467 – (Poster) STEM CELL MOBILIZATION FOLLOWING INITIAL THERAPY WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA – Monday, Dec. 8, 2008, 5:30 p.m.

Myelodysplastic Syndromes

#221 – (Oral) FINAL RESULTS FROM A PHASE I COMBINATION STUDY OF LENALIDOMIDE AND AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES – Monday, Dec. 8, 2008, 7 a.m.

#223 – (Oral) MAINTENANCE TREATMENT WITH 5-AZACITIDINE FOR PATIENTS WITH HIGH RISK MYELODYSPLASTIC SYNDROME (MDS) OR ACUTE MYELOID LEUKEMIA FOLLOWING MDS (MDS-AML) IN COMPLETE REMISSION (CR) AFTER INDUCTION CHEMOTHERAPY – Monday, Dec. 8, 2008, 7:30 a.m.

#225 – (Oral) HIGH RESOLUTION MOLECULAR ANALYSIS OF 5Q- SYNDROME PATIENTS AT DIAGNOSIS AND FOLLOWING LENALIDOMIDE THERAPY – Monday, Dec. 8, 2008, 8 a.m.

#227 – (Oral) THE EFFECT OF CONTINUED AZACITIDINE TREATMENT CYCLES ON RESPONSE IN HIGHER-RISK PATIENTS WITH MYELODYSPLASTIC SYNDROMES – Monday, Dec. 8, 2008, 8:30 a.m.

#1134 – (Poster) MAINTENANCE THERAPY LOW-DOSE AZACITIDINE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED OR REFRACTORY AML OR MDS: A DOSE AND SCHEDULE FINDING STUDY – Saturday, Dec. 8, 2008, 5:30 p.m.

#1653 – (Poster) MANAGEMENT AND SUPPORTIVE CARE MEASURES OF ADVERSE EVENTS (AES) IN HIGHER-RISK MDS PATIENTS (PTS) TREATED WITH AZACITIDINE (AZA) – Saturday, Dec. 6, 2008: 5:30 p.m.

#3636 – (Poster) AZACITIDINE PROLONGS OVERALL SURVIVAL (OS) AND REDUCES INFECTIONS AND HOSPITALIZATIONS IN PATIENTS WITH WHO-DEFINED ACUTE MYELOID LEUKEMIA COMPARED WITH CONVENTIONAL CARE REGIMENS – Monday, Dec. 8, 5:30 p.m.

#3269 – (Poster) EFFECTS OF AZACITIDINE VS. CONVENTIONAL CARE REGIMENS IN ELDERLY PATIENTS (>75 YEARS) WITH MYELODYSPLASTIC SYNDROMES FROM THE AZA-001 SURVIVAL TRIAL – Monday, Dec. 8, 2008, 5:30 p.m.

Non-Hodgkin’s Lymphoma

#262 – (Oral) CONFIRMATION OF THE EFFICACY AND SAFETY OF LENALIDOMIDE ORAL MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA: RESULTS OF AN INTERNATIONAL STUDY (NHL-003) – Monday, Dec. 8, 2008, 7:15 a.m.

#268 – (Oral) CONFIRMATION OF THE EFFICACY AND SAFETY OF LENALIDOMIDE ORAL MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS OF AN INTERNATIONAL STUDY (NHL-003) – Monday, Dec. 8, 2008, 8:45 a.m.

#1560 – (Poster) THE EFFICACY AND SAFETY OF LENALIDOMIDE ORAL MONOTHERAPY IN PATIENTS WITH MANTLE CELL LYMPHOMA PREVIOUSLY TREATED WITH BORTEZOMIB: POOLED DATA FROM TWO PHASE II STUDIES (NHL-002 AND NHL-003) – Saturday, December 6, 2008, 5:30 p.m.

#3058 – (Poster) LENALIDOMIDE AND RITUXIMAB ARE A PROMISING COMBINATION IN VITRO, IN VIVO PRECLINICALLY AND IN A PHASE I/II CLINICAL TRIAL IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA – Monday, Dec. 8, 2008, 5:30 p.m.

#3060 – (Poster) R²: PRELIMINARY RESULTS OF A PHASE II STUDY OF LENALIDOMIDE AND RITUXIMAB IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN’S LYMPHOMA (NHL) – Monday, Dec. 8, 2008, 5:30 p.m.

Chronic Lymphocytic Leukemia

#44 – (Oral) A PHASE II STUDY OF SINGLE-AGENT LENALIDOMIDE IN PREVIOUSLY UNTREATED, SYMPTOMATIC CHRONIC LYMPHOCYTIC LEUKEMIA – Sunday, Dec. 7, 2008, 4:45 p.m.

#45 – (Oral) LENALIDOMIDE AS INITIAL THERAPY FOR ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA – Sunday, Dec. 7, 2008, 5 p.m.

#2104 – (Poster) PRELIMINARY RESULTS OF A PHASE I/II, MULTI-CENTER, OPEN-LABEL STUDY (CLL-001) INVESTIGATING A STEPWISE DOSE-ESCALATION SCHEDULE OF LENALIDOMIDE IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA – Sunday, Dec. 7, 2008, 6 p.m.

#3168 – (Poster) TREATMENT WITH LENALIDOMIDE UPREGULATES CD40 EXPRESSION ON CLL CELLS AND INCREASES THEIR SENSITIVITY TO CD40-MEDIATED CYTOTOXICITY IN VITRO - Monday, Dec. 8, 2008: 5:30 p.m.

Amyloidosis

#1732 – (Poster) A MULTICENTER PHASE I/II DOSE ESCALATION STUDY OF LENALIDOMIDE IN COMBINATION WITH MELPHALAN AND DEXAMETHASONE IN SUBJECTS WITH NEWLY-DIAGNOSED LIGHT-CHAIN (AL)-AMYLOIDOSIS – Saturday, Dec. 6, 2008, 5:30 p.m.

#1734 – (Poster) PHASE I/II STUDY OF LENALIDOMIDE, INTERMEDIATE DOSE DEXAMETHASONE AND LOW-DOSE CYCLOPHOSPHAMIDE (RDC) FOR THE TREATMENT OF PATIENTS WITH PRIMARY SYSTEMIC AMYLOIDOSIS (AL) – Saturday, Dec. 6, 2008, 5:30 p.m.

Myelofibrosis

#663 – POMALIDOMIDE (CC-4047) THERAPY IN ANEMIC PATIENTS WITH MYELOFIBROSIS: RESULTS FROM A PHASE II RANDOMIZED MULTICENTER STUDY – Monday, Dec. 8, 2008, 5 p.m.

#662 – COMBINED THERAPY WITH LENALIDOMIDE AND PREDNISONE RENDERS DURABLE CLINICAL, HISTOPATHOLOGICAL AND MOLECULAR RESPONSES IN PATIENTS WITH MYELOFIBROSIS – Monday, Dec. 8, 2008, 4:45 p.m.

Pediatric Oncology

#107 – (Oral) LENALIDOMIDE (LMID) SIGNIFICANTLY ENHANCES CIRCULATING SERUM LEVELS OF IL-2 AND IL-15 LEVELS, NK EXPANSION AND ACTIVATION AND NK AND LAK CYTOTOXICITY IN CHILDREN WITH REFRACTORY/RECURRENT SOLID TUMORS: A CHILDREN’S ONCOLOGY GROUP PHASE I CONSORTIUM REPORT – Sunday, Dec. 7, 2008: 5:30 p.m.

*All times Pacific Standard Time

For more information and for complete abstracts, please visit http://ash.confex.com/ash/2008/webprogram/start.html

About Celgene International Sàrl

Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com.

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and those factors detailed in the Company's filings with the Securities and Exchange Commission such as 10K, 10Q and 8K reports.